<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialSourcesOutput><Sources><Source id="554391" type="PR">ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2004 Financial Results</Source><Source id="427712" type="PR">ImmunoGen announces favorable preliminary phase I/II data on huC242-DM1/SB-408075</Source><Source id="383091" type="PR">HuC242-DM1/SB-408075 enters second phase I/II clinical trial: ImmunoGen reaches fifth milestone in collaboration with SmithKline Beecham, triggering $2.0 million payment</Source><Source id="517357" type="CONFERENCE">Antibody Therapeutics - IBC's Inaugural Conference, San Diego, CA, USA</Source><Source id="430661" type="OTHER">A phase I study of SB-408075 administered as a single intravenous infusion once weekly in patients with advanced solid tumors</Source></Sources></trialSourcesOutput>